News Details

( 30/11/2017 15:37)
Cipla gets WHO nod to sell TB preventing drug in HIV patients

Cipla said it has received approval from the World Health Organisation (WHO) for Q-TIB, a combination drug indicated to help prevent tuberculosis infection in people living with HIV, reported PTI.

Q-TIB is a novel fixed dose combination in a single tablet and it is for the first time that such a combination has been made available in the world.

The company will market the product globally, Cipla said in a statement.

Q-TIB will help prevent tuberculosis infection in people living with HIV as they face a challenged immune system and are prone to infections, which constitute the major source of premature deaths among them.

As per WHO's Global TB Report, 2016, about one million people died of AIDS-related illness. Most of them succumbed to infections, and among them, 4 lakh died of tuberculosis.

ATTENTION INVESTORS 1 : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case | 2 : "Prevent Unauthorized Transactions in your demat / trading account --> Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors. | 3 : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

SEBI Regn. NSE: INB231280430 I F&O: INF231280430 I BSE: INB011280436 I NSE CD: INE231280430 I MCX-SX: INE261280430

Copyright © 2017 Rikhav Securities Ltd. All rights reserved

Designed , Developed & Content Powered by DION